Social Media Ideas for Bristol Myers Squibb

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug

Bristol Myers Squibb and MyoKardia have filed patent infringement suits in Delaware against a variety of pharmaceutical companies, including MSN Laboratories and Dr. Reddy's Labora...

<![CDATA[AstraZeneca and Bristol Myers Squibb Held Merger Talks: Report]]>

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

<![CDATA[Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory ]]>

<![CDATA[Pharmaceutical Executive Daily: AstraZeneca and Bristol Myers Squibb Held Merger Talks]]>

<![CDATA[Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors]]>

<![CDATA[Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia]]>

Bristol Myers Squibb launches Relopduo, its fixed-dose combination for skin cancer, in India

The dermatology-cancer drug received USFDA approval in 2022 for the treatment of adult and paediatric patients

Bristol-Myers Squibb stock rating held at Market Perform by Raymond James

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

<![CDATA[Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report ]]>

Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint

A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for...

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.

Bristol Myers Squibb expands NVIDIA AI infrastructure to support drug discovery

Bristol Myers Squibb, based in Princeton, said it will expand its computing infrastructure through a new deployment of NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, a move...

Bristol Myers Squibb says it will build $2.3B manufacturing campus in Houston

Bristol Myers Squibb announced Aug. 10 the selection of Houston as the site for a state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion inve...

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma

Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its...

AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says

Chai tees up Bristol Myers Squibb AI antibody discovery collab

A month after Chai Discovery tied up a major $400 million series C funding round, the AI drug discovery firm has teamed up with Bristol Myers Squibb.

<![CDATA[Pharmaceutical Executive Daily: Source Denies AstraZeneca-Bristol Myers Merger Talks]]>

Bristol Myers Squibb Picks Houston for $2.3B Manufacturing Campus

Bristol Myers Squibb plans a $2.3 billion Houston manufacturing campus that will create nearly 500 permanent jobs.

<![CDATA[Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report ]]>

AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.